Achieve Life Sciences
Committed to the development of cytisinicline as the first new Rx treatment for nicotine dependence in ~20 years.
Committed to the development of cytisinicline as the first new Rx treatment for nicotine dependence in ~20 years.
Achieve Life Sciences is a specialty pharmaceutical company with a focus on addressing the global smoking health epidemic, which is currently the leading cause of preventable death. Founded in 1991 and headquartered in the United States, the company is committed to advancing cytisine as a smoking cessation aid to overcome the global nicotine addiction epidemic. In its latest funding round, Achieve Life Sciences secured a significant $124.20M Post-IPO Equity investment on 29 February 2024, with contributions from Nantahala Capital, Propel Bio Partners, and Sopharma. This investment reflects the growing interest and support for the company's efforts in tackling the pressing issue of global smoking cessation within the Biotechnology, Health Care, and Pharmaceutical industries.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Debt | $10.00M | 1 | Silicon Valley Bank | 29 Jul 2024 |
| Post-IPO Equity | $124.20M | 3 |
|
29 Feb 2024 |
| Post-IPO Equity | $16.50M | - | 25 May 2023 | |
| Grant | $2.50M | 1 |
-logo.jpg){kind=logo}
|
01 Jun 2022 |
| Grant | $320.00K | 1 |
|
22 Jul 2021 |
No recent news or press coverage available for Achieve Life Sciences.
We care about your data, and we'd love to use cookies make your experience better.
